Physician‑Guided · HIPAA Compliant · Discreetly Delivered Nationwide
Physician-Supervised Access · GLP-1 Therapy
Ozempic®
Once-weekly semaglutide. Backed by landmark clinical trials and prescribed through a licensed telehealth consultation — when clinically appropriate for you.
You will be directed to our licensed telehealth partner to complete your consultation.
Ozempic® (semaglutide) is an injectable GLP-1 receptor agonist manufactured by Novo Nordisk. Originally developed for the management of type 2 diabetes, semaglutide has become one of the most studied metabolic medications of the past decade — with a growing body of evidence supporting its role in weight management and cardiovascular risk reduction. Through The Project Rx, patients can connect with a licensed provider via our telehealth partner to explore whether Ozempic® may be clinically appropriate for their individual situation.
What Is Ozempic®?
Ozempic® is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist available as a once-weekly subcutaneous injection. It was first approved by the U.S. Food and Drug Administration (FDA) in December 2017 for the treatment of type 2 diabetes mellitus in adults, and has since received additional indication for cardiovascular risk reduction in patients with type 2 diabetes and established heart disease.
Semaglutide belongs to a class of medications known as incretin mimetics. Incretins are hormones released by the gut in response to food intake; they signal the pancreas to release insulin and help regulate blood sugar. GLP-1 is one of the primary incretin hormones, and semaglutide is a synthetic analog designed to bind to and activate GLP-1 receptors throughout the body — but with a significantly longer half-life than the natural hormone.
The medication is administered via a prefilled injection pen once weekly, on the same day each week. It is available in three pen configurations delivering doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg — with patients typically starting at the lowest dose and titrating upward over several weeks under physician supervision.
While Ozempic® is FDA-indicated for type 2 diabetes, licensed providers may evaluate patients for other uses based on clinical judgment and individual health profile. A separate formulation of semaglutide — Wegovy® — is FDA-approved specifically for chronic weight management at the higher 2.4 mg dose.
The pharmacological durability of semaglutide is one of its defining characteristics. Its molecular structure has been modified to resist degradation by the enzyme DPP-4 and to bind reversibly to albumin in the bloodstream, extending its half-life to approximately one week — enabling the convenient once-weekly dosing schedule that has contributed to its broad clinical adoption.
2017
Year of FDA approval for type 2 diabetes
~7 days
Half-life of semaglutide in circulation
4 doses
Titration steps from 0.25 mg to 2 mg maintenance
Mechanism of Action
How Ozempic® Works
Semaglutide works by mimicking the action of the body's naturally occurring GLP-1 hormone — but with a crucial difference: where endogenous GLP-1 is broken down within minutes, semaglutide remains active in the bloodstream for approximately seven days, providing continuous receptor stimulation throughout the week with a single weekly injection.
GLP-1 receptors are found throughout the body — in the pancreas, brain, gastrointestinal tract, heart, kidneys, and liver — and activating them produces a coordinated set of metabolic effects. In the pancreas, GLP-1 receptor stimulation promotes glucose-dependent insulin secretion (insulin is released when blood glucose is elevated, but not when it is already low, which helps minimize hypoglycemia risk). It also suppresses glucagon secretion, a hormone that would otherwise raise blood glucose by triggering the liver to release stored glycogen.
In the gastrointestinal tract, semaglutide slows gastric emptying — the rate at which the stomach empties its contents into the small intestine. This slower transit time extends the period of satiety after meals, contributing to reduced overall caloric intake. Patients often report feeling full more quickly and less interested in food between meals.
In the brain, semaglutide acts on hypothalamic areas involved in appetite and energy regulation. GLP-1 receptors in the arcuate nucleus and other satiety centers respond to semaglutide signaling by reducing appetite and food-seeking behavior. This central effect is considered a key driver of the weight changes observed in clinical trials.
The combination of peripheral metabolic effects and central appetite modulation creates a multi-pronged mechanism that can influence body weight, glycemic control, and cardiovascular markers — making semaglutide one of the most pharmacologically complex medications in the metabolic space.
Glucose-Dependent Insulin Release
Semaglutide stimulates insulin secretion only in the presence of elevated blood glucose, helping to maintain glycemic control while reducing the risk of hypoglycemia.
Slowed Gastric Emptying
By reducing the rate at which the stomach empties after meals, semaglutide extends post-meal satiety and helps moderate caloric intake over the course of the day.
Central Appetite Modulation
GLP-1 receptors in the hypothalamus respond to semaglutide by suppressing appetite signals — reducing hunger and cravings at the neurological level.
Candidacy
Who May Be a Candidate
Determining whether Ozempic® is appropriate for a given patient requires a comprehensive clinical evaluation by a licensed provider. Because semaglutide was originally developed for type 2 diabetes management, it carries an FDA indication for adults with this diagnosis — and physicians may also consider its use off-label for related metabolic conditions based on individual patient factors.
Eligible patients typically undergo a review of their medical history, current medications, lab values, and health goals before a provider determines whether semaglutide may be an appropriate part of their care plan. The telehealth consultation through our licensed partner is designed to facilitate this evaluation in a thorough, HIPAA-compliant manner.
Ozempic® is not a weight-loss medication in the same sense as its sister formulation, Wegovy® — which carries an FDA indication specifically for chronic weight management. However, weight reduction is frequently observed as a secondary benefit in patients prescribed Ozempic® for glycemic control, and providers may weigh this when evaluating individual candidacy.
All prescription decisions are made solely by licensed medical professionals. The Project Rx facilitates access to the consultation process — we do not determine eligibility, prescribe medications, or fulfill prescriptions. Your provider will outline the most appropriate treatment options for your individual health profile during your consultation.
May Be Appropriate If
- ›Adults with type 2 diabetes not adequately controlled by diet and exercise alone
- ›Patients seeking cardiovascular risk reduction alongside diabetes management
- ›Adults with BMI considerations and associated metabolic risk factors
- ›Patients who have discussed GLP-1 therapy with a primary care provider
- ›Individuals without personal or family history of medullary thyroid carcinoma
- ›No current diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN2)
Not Typically Appropriate If
- —Personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- —Current or history of pancreatitis
- —Type 1 diabetes (semaglutide is not indicated)
- —Pregnancy or planning pregnancy
- —Known hypersensitivity to semaglutide or excipients
Dosing Overview
Titration Schedule
Ozempic® is initiated at a low dose and titrated upward over several weeks to improve tolerability, particularly with respect to gastrointestinal side effects. The standard titration schedule is designed to allow patients' bodies to adjust gradually to the medication's effects on gastric motility and appetite.
The starting dose of 0.25 mg is considered a therapeutic introduction rather than a clinically effective dose for glycemic control — its purpose is acclimation. Most patients begin to experience meaningful glycemic and appetite effects once they reach the 0.5 mg or 1 mg dose levels.
Your prescribing provider will determine the appropriate titration pace based on your response and tolerability. Not all patients advance to the maximum 2 mg dose — many achieve satisfactory outcomes at 0.5 mg or 1 mg, and dose decisions should always be made in consultation with your licensed provider.
The injection is administered subcutaneously (beneath the skin) in the abdomen, thigh, or upper arm, rotating injection sites weekly. Ozempic® pens are pre-filled and come with easy-to-use needles included in the kit.
Weeks 1–4
Initiation dose — tolerability phase
0.25 mg/week
Weeks 5–8
First therapeutic dose
0.5 mg/week
Weeks 9–12
Standard maintenance for most patients
1 mg/week
Week 13+
Maximum dose — if additional control needed
2 mg/week
* Dose adjustments are determined by your prescribing provider based on response and tolerability. Not all patients advance to higher doses.
Clinical Evidence
What the Research Shows
26%
Reduction in major cardiovascular events vs. placebo
SUSTAIN-6 trial
~4–6 kg
Average weight reduction across SUSTAIN program trials
SUSTAIN 1–5 pooled
−1.5%
Average HbA1c reduction at 1 mg dose vs. placebo
SUSTAIN-1
The evidence base for semaglutide is extensive, built on a comprehensive clinical trial program called SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes). The SUSTAIN trials enrolled thousands of patients across multiple countries and established semaglutide's efficacy for glycemic control, weight reduction, and cardiovascular risk.
SUSTAIN-6, the landmark cardiovascular outcomes trial, demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) — including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death — in adults with type 2 diabetes at elevated cardiovascular risk. This cardiovascular benefit is part of the FDA-approved indication for Ozempic® in appropriate patients.
Across the SUSTAIN program, semaglutide consistently demonstrated superior HbA1c reductions compared to placebo and several active comparators, including other GLP-1 agents. Weight reductions observed across the trials ranged from approximately 4 kg to 6 kg on average, with higher doses and longer durations associated with greater effect.
It is important to note that clinical trial results reflect averages across large populations. Individual responses vary considerably based on baseline characteristics, adherence, lifestyle factors, and other variables. Your provider will discuss realistic expectations based on your personal health profile during the consultation.
Safety Information
Side Effects & Risks
Like all medications, Ozempic® carries a risk of side effects. The most commonly reported side effects are gastrointestinal in nature and tend to be most pronounced during the initial weeks of treatment and following dose increases. For the majority of patients, these effects are mild to moderate and diminish as the body adjusts to the medication.
Nausea is the most frequently reported side effect, affecting a significant proportion of patients particularly during dose escalation. Slower titration — spending more time at lower doses before advancing — can help reduce the severity of gastrointestinal symptoms. Eating smaller meals, avoiding high-fat foods, and staying well hydrated are commonly recommended strategies for managing GI side effects.
The prescribing provider and clinical support team available through your licensed telehealth provider will guide you through managing side effects and adjusting your treatment approach as needed. Transparent communication about your experience during treatment is essential to optimizing outcomes.
Common (≥1 in 10)
- · Nausea (most common, often transient)
- · Diarrhea
- · Vomiting
- · Constipation
- · Abdominal pain or discomfort
- · Decreased appetite
- · Indigestion / heartburn
Serious Risks (Discuss with Provider)
- · Pancreatitis (discontinue if suspected)
- · Gallbladder disease (cholelithiasis)
- · Thyroid C-cell tumors (animal data; avoid in MTC/MEN2 history)
- · Acute kidney injury (particularly with dehydration from GI side effects)
- · Diabetic retinopathy complications (in patients with pre-existing retinopathy)
- · Serious hypersensitivity reactions (rare)
This is not a complete list of possible side effects. Before starting Ozempic®, disclose your full medical history, current medications, supplements, and allergies to your prescribing provider. The FDA label for semaglutide contains complete safety and prescribing information. Your licensed provider will review the benefit-risk profile with you individually and help you determine whether this medication is appropriate for your situation.
How It Works
The Consultation Process
The Project Rx facilitates access to a licensed telehealth consultation for patients who want to explore whether Ozempic® may be clinically appropriate for them. We work with a licensed telehealth partner — LegUp Health — whose network of licensed providers can conduct thorough evaluations, request labs if needed, and issue prescriptions through licensed pharmacies for clinically eligible patients.
The process is designed to be thorough, efficient, and entirely online — from your initial intake through ongoing follow-up. Every step is HIPAA-compliant and handled by licensed medical professionals. The following steps outline what to expect from start to prescription.
Complete Your Intake
Fill out a comprehensive health questionnaire covering your medical history, current medications, weight history, and health goals. This information is reviewed by a licensed provider before your consultation.
Provider Review & Consultation
A licensed provider reviews your intake information and conducts a telehealth consultation to assess your eligibility, ask follow-up questions, and discuss treatment options appropriate for your situation.
Lab Work (if needed)
Your provider may order baseline lab work — including metabolic panels, HbA1c, and thyroid markers — to inform prescribing decisions. Lab orders are coordinated through the telehealth platform.
Prescription Issuance
If clinically appropriate, your provider issues a prescription for Ozempic® to a licensed pharmacy of your choice. Most patients can fill prescriptions at retail or mail-order pharmacies, and insurance coverage options are discussed.
Ongoing Care & Monitoring
Your provider remains available for follow-up consultations, dose adjustments, side effect management, and progress monitoring throughout your treatment course.
What to Expect
Month-by-Month Overview
Every patient's experience with Ozempic® is different. The following is a general overview of what many patients report across the first several months of treatment — though individual results vary based on baseline health, dosing, lifestyle factors, and adherence. These are not guarantees; they are patterns observed across patient populations in clinical settings.
It is common for patients to experience some degree of GI adjustment in the first weeks, followed by a gradual shift in appetite and energy patterns as the medication reaches therapeutic levels. Weight changes, when they occur, typically develop gradually over months — not days. Patience and consistent provider communication are essential components of a successful treatment experience.
Initiation & Adjustment
The 0.25 mg starting dose is an acclimation phase. Some patients experience mild nausea or reduced appetite. Glycemic effects are limited at this dose. Focus on adherence and documenting any side effects.
First Therapeutic Dose
At 0.5 mg, many patients begin to notice meaningful changes in appetite, early satiety, and food cravings. Fasting glucose levels and post-meal spikes may begin to improve. GI side effects may peak during dose transition then subside.
Sustained Metabolic Effects
At 1 mg, most patients are at or approaching their target dose. HbA1c improvements become measurable. Weight changes, if occurring, are often more pronounced. Many patients report reduced food noise and improved relationship with eating.
Long-Term Maintenance
With consistent dosing and provider monitoring, metabolic benefits typically continue to build. SUSTAIN trials tracked outcomes to 40–104 weeks, demonstrating durable HbA1c and weight effects with ongoing treatment.
FAQ
Frequently Asked Questions
Access & Pricing
Starting at $936/month
Medication cost is an estimate based on current market pricing without insurance coverage. Actual cost varies by pharmacy, dosage, and insurance plan. Your licensed provider will discuss options during consultation.
Begin Your ConsultationEligibility is determined by a licensed provider following your consultation. Not all patients qualify for a prescription.
Ozempic® is a registered trademark of Novo Nordisk A/S. The Project Rx is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names appearing on this page are used solely for informational identification of the referenced medications. The Project Rx facilitates access to licensed telehealth consultations; we do not manufacture, sell, or dispense prescription medications. All prescription decisions are made exclusively by licensed medical professionals following a clinical evaluation. This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or changing any medication.